New research reveals that individuals who discontinue popular slimming jabs like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who end conventional lifestyle programs.
Published data in a leading health publication shows that while overweight people frequently drop a large proportion of their total mass while on the medication, the weight returns at an average rate of nearly a kilo each month after stopping.
"Individuals buying such treatments should be aware of the danger of rapid weight regain when the treatment concludes," stated expert Dr. Susan Jebb.
That rate of recovery suggests a return to starting mass within about a year and a half.
Weighing Therapies
The research, which looked at dozens of studies involving over 9,000 of patients, compared the results of GLP-1 agonists with older methods.
Researchers emphasize that people who shed pounds through lifestyle changes alone generally have a less rapid weight regain—around 100 grams monthly—once they finish.
Understanding the Quick Rebound
Experts suggest the mode of action of the jabs accounts for the amplified weight return.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Artificially providing GLP-1 concentrations far above than normal could lead to the body to produce less of its own natural hormone, and could reduce responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this medication means hunger is uncontrolled, making binge eating a significant risk."
An Ongoing Condition?
Health authorities suggest the jabs for individuals with weight-linked health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians argue that, given the high risk of weight regain, the therapy should be considered long-term.
This opinion is echoed by drug manufacturers, who note that the results "underscore the chronic nature of excess weight," akin to managing conditions like hypertension.
Patient Experiences
People who have come off the jabs explain a powerful resurgence of cravings.
"It was like a trigger that goes on and I was suddenly ravenous," said one woman.
The struggle is exacerbated if users have not established lasting lifestyle or habit modifications during treatment.
Significant Use
Survey data show that a significant number of people in the UK have tried these injections in the last 12 months, with interest continuing to grow.
- Adoption is more common among females than men.
- The middle-aged age group shows the greatest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
Finally, experts stress that while these medications are potent agents for weight loss, they are not a permanent fix and long-term success likely depends on combined lifestyle support.
